J P N Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.44 Cr
as on 16-11-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.07 Cr
as on 16-11-2024
- Revenue 3.33%
(FY 2023)
- Profit 46.76%
(FY 2023)
- Ebitda 49.49%
(FY 2023)
- Net Worth 23.29%
(FY 2023)
- Total Assets 24.35%
(FY 2023)
About J P N Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.44 Cr.
The company has closed loans amounting to ₹4.07 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jayesh Shah and Mukund Shah serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC145446
- Company No.
145446
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does J P N Pharma Private Limited offer?
J P N Pharma Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Aldehydes, Digestive System Drugs & Medicines, Laxatives, Cardiovascular Drugs & Medication, Kidney Drugs, Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, API (Active Pharmaceutical Ingredients), Chemical Intermediates.
Who are the key members and board of directors at J P N Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayesh Shah  | Director | 31-Mar-2004 | Current |
| Mukund Shah | Director | 31-Mar-2004 | Current |
Financial Performance of J P N Pharma.
J P N Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.33% increase. The company also saw a substantial improvement in profitability, with a 46.76% increase in profit. The company's net worth Soared by an impressive increase of 23.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of J P N Pharma?
In 2023, J P N Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shri Vinayak Chemex (India) Pvt.Ltd.Active 32 years 3 monthsJayesh Shah and Mukund Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Sep 2006 | ₹3.90 Cr | Satisfied |
Bank Of Baroda Creation Date: 31 Jan 2005 | ₹1.70 M | Satisfied |
How Many Employees Work at J P N Pharma?
J P N Pharma has a workforce of 55 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of J P N Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped J P N Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
